KEY TAKEAWAYS
- The study aimed to assess the effect of Peptide Radionuclide Radiation Therapy with Lutathera® treatment on 3DVGR in nonanaplastic meningiomas.
- The results indicated delayed onset of Lutathera®’s antitumoral effects in nonanaplastic meningiomas, with sustained activity observed up to 18 months.
Various retrospective studies and meta-analyses exploring Peptide Radionuclide Radiation Therapy in brain cancer indicate an improvement in six-month progression-free survival (PFS) for WHO grade 1 and 2 meningiomas.
Thomas Graillon and his team spearheaded a study that aimed to assess the effect of Lutathera® treatment with Peptide Radionuclide Radiation Therapy on the three-dimensional volume growth rate (3DVGR) in nonanaplastic meningiomas.
The study was conducted retrospectively, involving 8 patients who received treatment with Lutathera®. Volume measurements were obtained using millimetric 3D T1-weighted MRI sequences with gadolinium enhancement. The tumor growth rate was categorized using a previously described 3DVGR classification (Graillon et al.).
Patients presented with seven WHO grade 2 meningiomas and one aggressive WHO grade 1. All patients, with the exception of 1, underwent 4 treatment cycles. The 3DVGR significantly decreased at 3, 6, and 12 months after treatment initiation when analyzing each lesion separately.
The mean and median 3DVGR from all patients was 29.5% and 44.5%/6 months before treatment initiation, then 16.5% and 25%/6 months at three months post-treatment initiation, 9.5% and 4.5%/6 months after 6 months, as well as 9.5% and 10.5%/6 months after 12 months. At 3, 6, and 12 months after treatment initiation, 4/8, 6/7, and 5/6 patients were class 2 (stabilization or severe 3DVGR slowdown), respectively. No patient was class 1 at 6 and 12 months, suggesting a lack of drug response.
The study concluded that in nonanaplastic meningiomas, the antitumoral activity of Lutathera® was initially delayed and more evident at six months, with no significant response observed during treatment. Additionally, this antitumoral effect was sustained for 12–18 months after treatment initiation.
Authors declare no receipt of funds, grants, or other support during the preparation of this manuscript.
Source: https://link.springer.com/article/10.1007/s11060-024-04622-5
Graillon, T., Salgues, B., Horowitz, T. et al. (2024). “Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.” J Neurooncol (2024). https://doi.org/10.1007/s11060-024-04622-5
